Bristol-Myers bumps off chief scientist in another big shakeup, bringing in Celgene and Novartis execs

Just 2 years after Tom Lynch stepped from the board room to the top scientific position at Bristol-Myers Squibb, he’s out. The pharma giant reported Wednesday morning that Lynch will leave his post as CSO in four months, moving Celgene R&D exec Rupert Vessey into the top research position after the big merger while recruiting Novartis oncology development head Samit Hirawat for chief medical officer with command of the development group.